COGT

Cogent Biosciences, Inc.

Insider Trades

NameValueActionPriceCurrent Price
Fairmount Funds Management LLCDirector
$243M7M shares
SellMar 31, 2026
$34.66
--
Fairmount Funds Management LLCDirector
$127M3.5M shares
SellJan 22, 2026
$36.40
--
Green John L.Chief Financial Officer
$3.0M77k shares
SellDec 26, 2025
$38.68
--
Kearns EvanChief Legal Officer
$2.5M65k shares
SellDec 26, 2025
$38.70
--
Robinson John EdwardChief Scientific Officer
$3.5M90k shares
SellDec 26, 2025
$38.74
--
Sachs JessicaChief Medical Officer
$3.2M82.6k shares
SellDec 26, 2025
$38.70
--

News

seekingalpha.comCogent Biosciences: A Pre-Commercial Biotech With Commercial-Stage Leverageseekingalpha.comJun 14globenewswire.comCogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congressglobenewswire.comJun 12globenewswire.comCogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congressglobenewswire.comJun 12globenewswire.comCogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meetingglobenewswire.comMay 30globenewswire.comCogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meetingglobenewswire.comMay 30